Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
3d
GlobalData on MSNEli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASHLilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.
Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...
Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth ...
The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is ...
Since joining Lilly in 2022, Winselow has served as Group Vice President and Chief Commercial Officer of Lilly Oncology.
Eli Lilly & Co. is tapping the U.S. investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase ...
Eli Lilly and Company has announced the appointment of Winselow Tucker as President and General Manager for Lilly India, ...
Eli Lilly has named Winselow Tucker as President and General Manager for India. Tucker will oversee operations, including the Lilly India commercial organization and the Lilly Capability Centre India.
Eli Lilly and Company (Lilly) announced the appointment of Winselow Tucker as president and general manager for Lilly India, effective immediately.
South Korea-based developer of RNAi therapeutics developer OliX Pharmaceuticals has announced a global licensing agreement with Eli Lilly.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results